The Oxford Parkinson's Disease Centre (OPDC) is a unique multidisciplinary research program at the University of Oxford. The OPDC was established in February 2010 and brings together internationally-renowned scientists who work on the genetics of Parkinson’s, the generation of cell and animal models, and the wiring of brain circuits which control movement, with clinical experts in the diagnosis and treatment of Parkinson’s.
Our world-class research centre works to understand the earliest events in the development of Parkinson’s with an ultimate view to target the molecular mechanisms of disease with neuroprotective therapies to prevent disease onset or delay progression.
Our program is focused on the molecular pathways to Parkinson’s in order to:
- Understand the progression of Parkinson’s
- Predict the onset of Parkinson’s
- Identify potential drug targets for Parkinson’s
- Develop new treatments that will prevent the development of Parkinson’s in at-risk individuals.
Watch the video below to learn more about OPDC's research:
Tuesday, 24 May 2022, 12pm to 1pm
Monday, 27 June 2022, 2pm to 3pm
Hyperexcitability in young iPSC-derived C9ORF72 mutant motor neurons is associated with increased intracellular calcium release.
Burley S. et al, (2022), Sci Rep, 12
Dietary Patterns and Nonmotor Symptoms in Parkinson's Disease: A Cross-Sectional Analysis.
Lawrie S. et al, (2022), J Am Nutr Assoc, 1 - 10
A composite clinical motor score as a comprehensive and sensitive outcome measure for Parkinson's disease.
Lo C. et al, (2022), J Neurol Neurosurg Psychiatry
Mapping brain structural differences and neuroreceptor correlates in Parkinson's disease visual hallucinations.
Vignando M. et al, (2022), Nat Commun, 13
Dopamine release in nucleus accumbens is under tonic inhibition by adenosine A1 receptors regulated by astrocytic ENT1 and dysregulated by ethanol.
Roberts BM. et al, (2022), J Neurosci
Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies.
Poggiolini I. et al, (2021), Brain